

An evaluation of the emerging vaccines and immunotherapy against staphylococcal pneumonia in children

arr a ll[†], l r a[†], *[†]

Abstract

B : a l a r a al a a ar .l al l a al a l a l r a r l r a r a l r a r a , all a ar r , - r r , r a al a ar r a a r a la r. r a a , al a l al a r a r a all. r r l r ar a l a a a r a a a a .a r l al a ar a a a a .

M : a l l r r r al r ar . a a .l a l, a all r l r r r la r a a a a l a r r l a r r a r a r a l , l , r a l a , a a , l r a l , a r a l a a a l , a al a a r r , a a l r a al r r , a .l a ll, a r r (l a a , r a al l al r ar r, r a al l a r a r r a ar a al a) ar a . l a r a r r r a a r a a , r a r l r a r r " ll " ar a r r a a al r %.

* r r r a al.
†

19 (F 1). 3
2009 (A 2010)

ED I E,

, G 5 C

(I I , B

B)

(GA I, H , ICEF

ADI). D

A 1.

CHNRI - II:

20

20

()

20


5 ()

)

F

(20%)


A



Fg 1

S. aureus, H I B 29. I E I B
 aureus. I B (I B), S. aureus 710 I B 28.
 S. aureus (40%)
 S. aureus (F 5).

Passive immunization approach



E

Active immunization

CP5 /CP8 Conjugate vaccines (StaphVAX, TriStaph, PentaStaph)


3 A

III 1804
35 A

80
) 80%
C 8. H
3 54

(C 5 75%
26%

Passive immunization against S. Aureus



aureus . H

S.

8

III
S. aureus.

A III 3600

A (" ://)

21 2006

:"

(3. 5)

5 F 6).

D
D

I
A
E 31%

S. aureus

H

59.5

5

A

A

5

5 A

aureus

60. H

A

H

I 2007, H

A H, B & G

F

F F I (IFFI),

GA I A 70

A

C (A C). E 2005. C

G D

F ; GA I A ; B & G

A C

B

60%

(F 5 F 6). H

(40%)

)

A

S. aureus

? A

S. aureus.

A S. aureus



ar . ar a , r
a a ll a r ara r a r . ar a
a r all r , a a ll , a al a al , a a r r a
a r , a a ll , a a ll a r all r a r .
a r r a a r r a a r al r
a r l a , ar a l ra r
r , a a ll , a a r r a , a r all r ra
a r . ll a r r a a a r al a r .

C
a l lar a a r
r a r a l a r
ar a al l l r
a a *Staphylococcus aureus* (l a r) .

Published: 13 April 2011

R
la , a , a l , a a , a
a ll , al r , l , a r , a r Global,
regional, and national causes of child mortality in 2008: a systematic
analysis. *Lancet* , 375(9730)
Staphylococcus aureus infections. *N Engl J Med* ,
339(8)
The prospects for developing a vaccine against *Staphylococcus*
aureus. *Trends Microbiol* , 4(4)
Efficient detection
and long-term persistence of the carriage of methicillin-resistant
Staphylococcus aureus. *Clin Infect Dis* , 19(6)
National Nosocomial Infections Surveillance (NNIS) System Report, data
summary from January 1992 to June 2002, issued August 2002. *Am J*
Infect Control , 30(8)
Pneumonia caused by methicillin-
resistant *Staphylococcus aureus*. *Clin Infect Dis* , 46(Suppl 5)
Clinical characteristics and treatment patterns among patients
with ventilator-associated pneumonia. *Chest* , 129(5)
Staphylococcal vaccines and immunotherapies. *Infect*
Dis Clin North Am , 23(1)
Predominance of two
newly described capsular polysaccharide types among clinical isolates of
Staphylococcus aureus. *Diagn Microbiol Infect Dis* , 2(2)
Intermediate vancomycin susceptibility in a community-
associated MRSA clone. *Emerg Infect Dis* , 13(3)
Vancomycin-resistant *Staphylococcus aureus* isolates associated with
Inc18-like vanA plasmids in Michigan. *Antimicrob Agents Chemother* ,
52(2)
Setting
priorities in global child health research investments: addressing values
of stakeholders. *Croat Med J* , 48(5)
The complex challenge of setting priorities in health research
investments. *Indian J Med Res* , 129(4)
Setting priorities in global child health research
investments: universal challenges and conceptual framework. *Croat Med*
J , 49(3)
Childhood pneumonia and
diarrhoea: setting our priorities right. *Lancet Infect Dis* , 7(1)
Setting priorities in
global child health research investments: assessment of principles and
practice. *Croat Med J* , 48(5)
Research priorities to reduce global

mortality from newborn infections by 2015. *Pediatr Infect Dis J* , 28(1
Suppl)
Setting research priorities to reduce
global mortality from childhood diarrhoea by 2015. *PLoS Med* ,
6(3)
Setting priorities in global child health research investments:
guidelines for implementation of CHNRI method. *Croat Med J* ,
49(6)
Setting priorities in child health research
investments for South Africa. *PLoS Med* , 4(8)
Setting
priorities for global mental health research. *Bull World Health Organ* ,
87(6)
Research
priorities for health of people with disabilities: an expert opinion
exercise. *Lancet* , 374(9704)
Method
for the serological typing of the capsular polysaccharides of
Staphylococcus aureus. *J Clin Microbiol* , 22
Capsular
antibodies induce type-specific phagocytosis of capsulated
Staphylococcus aureus by human polymorphonuclear leukocytes. *Infect*
Immun , 56
Serotyping and
electron microscopy studies of *Staphylococcus aureus* clinical isolates
with monoclonal antibodies to capsular polysaccharide types 5 and 8.
J Clin Microbiol , 25(3)
(ar a ()- ra)-a , a , ar a

Phase II, randomized, double-blind, multicenter study comparing the safety and pharmacokinetics of tefibazumab to placebo for treatment of Staphylococcus aureus bacteremia. *Antimicrob Agents Chemother* , 50(8) - .

Late-onset sepsis in very low birth weight neonates: the experience of the NICHD Neonatal Research Network. *Pediatrics* , 110(2 Pt 1) - .

